中国大型完全性17α-羟化酶缺陷队列中CYP17A1新变异及功能验证
该研究纳入113例经基因确诊的完全性17α-羟化酶缺陷患者,收集临床、激素及影像数据,通过测序鉴定CYP17A1变异,并体外验证致病性。共发现50种致病性变异,包括6种新变异,c.985_987delinsAA占59.29%等位基因,并揭示剪接异常新机制。
要点
- 中国完全性17-OHD队列中c.985_987delinsAA为 founder 热点,占59.29%等位基因。
- c.286C>G、c.436+1G>T、c.1241C>T、c.1300C>T、c.1348C>T、c.1433G>T为6种新致病性变异。
- 部分错义变异通过异常剪接致病,拓展了CYP17A1变异致病机制。
核心结论
- 研究描绘了中国完全性17-OHD最全面的CYP17A1变异谱,发现6种新致病性变异并确认剪接异常为被低估的致病机制。
- c.985_987delinsAA在中国人群中存在奠基者效应,对遗传诊断和咨询有重要价值。
研究设计与样本
- 研究纳入来自107个无亲缘关系家庭的113例经基因确诊的完全性17-OHD患者,收集临床表现、激素和影像数据。
- 采用Sanger测序、全外显子组测序或长读长测序鉴定CYP17A1变异,并开展酶活性测定和小基因剪接试验进行体外功能验证。
主要发现
- 所有患者均表现为表型女性,中位诊断年龄17岁;高血压占93.58%,低钾血症占74.31%,91.26%乳腺Tanner I期。
- 共鉴定50种致病性CYP17A1变异,包括6种新变异(c.286C>G、c.436+1G>T、c.1241C>T、c.1300C>T、c.1348C>T、c.1433G>T)。
- 变异谱以c.985_987delinsAA为热点,占59.29%等位基因,突变聚集于外显子6和8。
- 体外酶活性试验显示除p.Val236Gly保留极微残余活性外,所有变异几乎完全丧失17α-羟化酶和17,20-裂解酶活性。
- 小基因试验显示5种变异(包括2种错义变异c.1084C>T和c.1085G>A)破坏前mRNA正常剪接,揭示蛋白功能异常和RNA加工异常双重致病机制。
临床怎么用
- 对临床疑诊完全性17-OHD患者,可优先筛查c.985_987delinsAA热点变异以提高基因诊断效率。
- 对新发现的错义变异应结合酶活性及剪接功能试验综合判读致病性,避免仅凭蛋白功能预测漏诊剪接异常。
- 遗传咨询中应考虑中国人群c.985_987delinsAA的奠基者效应,指导家系筛查和产前诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complete 17α-hydroxylase/17,20-lyase deficiency (17-OHD) is a rare autosomal recessive form of congenital adrenal hyperplasia caused by CYP17A1 variants. Large-scale studies integrating clinical, genetic, and functional data remain limited. METHODS: We recruited 113 genetically confirmed 17-OHD patients from 107 unrelated families. Comprehensive clinical manifestations, hormonal, and imaging examination data were collected. CYP17A1 variants were identified by Sanger sequencing, whole-exome sequencing or long-read sequencing. In vitro functional studies including enzyme activity assays and minigene splicing assays were performed to verify the pathogenicity of the variants. RESULTS: All patients presented as phenotypic females, with a median diagnostic age of 17 years. Hypertension (93.58%) and hypokalemia (74.31%) were the dominant clinical features, and 91.26% exhibited Tanner stage I breast development. We identified 50 pathogenic CYP17A1 variants, including 6 novel ones (c.286C>G, c.436+1G>T, c.1241C>T, c.1300C>T, c.1348C>T, c.1433G>T). The mutation spectrum was dominated by a founder hotspot, c.985_987delinsAA, accounting for 59.29% of alleles, with mutations clustering in exons 6 and 8. In vitro enzyme activity assays confirmed near-complete loss of both 17α-hydroxylase and 17,20-lyase activities in all variants except p.Val236Gly, which retained minimal residual activity. Notably, 5 variants (including 2 missense changes, c.1084C>T and c.1085G>A) were shown to disrupt normal pre-mRNA splicing in minigene assays, revealing a dual molecular mechanism of pathogenicity involving both protein dysfunction and aberrant RNA processing. CONCLUSION: This study defines the most comprehensive CYP17A1 variant spectrum for complete 17-OHD in China, identifies 6 novel pathogenic variants, and uncovers splicing disruption as an under-recognized mechanism in missense mutations. These findings expand the molecular and clinical understanding of 17-OHD, highlight the founder effect of c.985_987delinsAA in the Chinese population, and provide critical insights for genetic diagnosis and counseling.
引用
- Cao Y, Lu L, Li M, et al. Novel CYP17A1 variants and functional validation in a large Chinese cohort of complete 17α-hydroxylase deficiency. J Clin Endocrinol Metab. 2026. PMID: 41860303. doi:10.1210/clinem/dgag049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。